The Future Of Gastroenterology Medicine
ADH Research Institute, a division of Arizona Digestive Health, brings the future of gastroenterology medicine to Adults in the Phoenix-Scottsdale area. We strive to provide all patients, current and new, with access to cutting edge treatments prior to them being granted FDA approved.
For new treatments and therapies to receive FDA approval, the investigational product must pass through four different phases: Phase 1, Phase 2 and Phase 3, are pre-FDA approval, while Phase 4 is considered post-FDA approval. ADH Research Institute participates in all four Phases, 1 through 4, with our primary focus in Phase 2 and Phase 3 of the clinical research testing phase.
Months to Years
Years to Decades
Our current treatment options include but are not limited to the following conditions: Crohn’s Disease, Ulcerative Colitis, Inflammatory Bowel Disease, Irritable Bowel Syndrome, Celiac Disease, Gastroesophageal Reflux Disease or GERD, Gastroparesis, Non-alcoholic Steatohepatis or NASH, Fatty Liver Disease, Hepatitis B, Hepatitis C, Clostridium Difficile or C. Diff, Helicobacter Pylori, or H. Pylori, and Eosinophilic Esophagitis or EoE.
Please click on the Clinical Trials button above to see a list of enrolling clinical trials.